The Digital Diabetes Patient Reminder (DIPAR) Tool For Adults With Type 2 Diabetes
DIPAR RCT
1 other identifier
interventional
200
1 country
2
Brief Summary
Digital health tools may present an opportunity to address these challenges by enhancing care delivery, improving patient engagement, and facilitating better disease management for chronic diseases such as type 2 diabetes mellitus (T2DM). This primary objective of this randomized controlled trial is to evaluate whether the Diabetes Digital Patient Reminder (DIPAR), embedded in patient portal, can increase the proportion of T2DM patients who have their albuminuria measured at least once annually by either a general practitioner (GP) or a diabetes specialist, as documented in their hospital medical records (EMD), thereby reflecting active monitoring of diabetes-related parameters.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2025
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 24, 2025
CompletedStudy Start
First participant enrolled
October 6, 2025
CompletedFirst Posted
Study publicly available on registry
December 2, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
February 19, 2026
February 1, 2026
1.7 years
September 24, 2025
February 18, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Documentation rate of Albuminuria
Defining the proportion of patients with at least one measured and documented albuminuria value in the electronic medical dossier
12 months post intervention
Secondary Outcomes (10)
Documentation rate of HbA1c (2x)
12 month post intervention
Documentation rate of HbA1c (1x)
12 month post intervention
DIPAR Usability
12 months post intervention
DIPAR Acceptability
12 months post intervention
Change in HbA1c
Baseline, Month 6 and Month 12 post intervention
- +5 more secondary outcomes
Study Arms (2)
DIPAR Intervention Group
EXPERIMENTALStandard of Care and the Digital DIPAR Intervention (reminder function + consultation dashboard)
Control Group
OTHERStandard of Care
Interventions
\- Reminder function: participants will receive reminders that align with the minimal follow-up requirements in Belgium, when the HbA1c and albuminuria measurements are overdue o Notification schedule: HbA1c: First reminder after 7 months without a measurement; second reminder 4 weeks later if still overdue. Albuminuria: First reminder after 13 months without a measurement; second reminder 4 weeks later if still overdue. \- Consultation dashboard: this feature will allow the display selected diabetes clinical parameters in a visual and colorful display. The selected parameters are: HbA1c (%), LDL-C (mg/dl), systolic and diastolic blood pressure (mmHg), albuminuria (mg/gACR), eGFR (ml/min/1.73m2) and BMI (weight/lenght2). Furthermore, participants will be provided with a questionnaire that targets selfcare behaviors and are required to complete this before consultations with their diabetes-specialist or general practitioner.
This allows for the control to group to receive only their routine consultation and follow-up care as provided by their diabetes specialist.
Eligibility Criteria
You may qualify if:
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures;
- Adults 18 years or older;
- Treated and followed-up for Type 2 diabetes at the department of endocrinology at the participating hospitals;
- Patients with (the ability to access) the MyNexuz patient portal;
- Patients with the ability to understand Dutch, French or English.
You may not qualify if:
- Participant is pregnant or hospitalized at the time of recruitment;
- Are unable to use a mobile phone because of mental or cognitive impairment;
- Deemed ineligible by the treating physicians.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- KU Leuvenlead
- Regionaal Ziekenhuis Heilig Hart Tienencollaborator
- Universitaire Ziekenhuizen KU Leuvencollaborator
Study Sites (2)
Regional Hospital of Leuven
Leuven, Flemish Brabant, 3000, Belgium
University Hospital of UZ Leuven
Leuven, Flemish Brabant, 3000, Belgium
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Roman Vangoitsenhoven, Prof Dr.
Universitaire Ziekenhuizen KU Leuven
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Randomization will be carried out by an external person to the study and the data will be analyzed by an external extension
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dr., MD, PhD
Study Record Dates
First Submitted
September 24, 2025
First Posted
December 2, 2025
Study Start
October 6, 2025
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2027
Last Updated
February 19, 2026
Record last verified: 2026-02